Biomarker Panel Modeling for Subtle MS Activity Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for predicting multiple sclerosis (MS) disease activity are limited by low sensitivity, specificity, and predictive power, particularly in distinguishing subtle disease activity and differentiating MS from other neurological conditions.
Innovation Solution
A multivariate biomarker panel comprising specific biomarkers (e.g., NEFL, MOG, CXCL9, OPG, OPN, CXCL13, GFAP) is used to generate predictions of MS disease activity through a predictive model, improving sensitivity and specificity by incorporating shifts in biomarker levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If individual biomarkers are used to predict multiple sclerosis disease activity, then the testing process is simple, but the sensitivity and ability to detect subtle disease activity is low
Solution Approach 1:
The patent combines multiple individual biomarkers into a unified multivariate biomarker panel that collectively predicts multiple sclerosis disease activity. This merging approach integrates the predictive capabilities of various biomarkers (such as neurodegeneration markers, inflammation markers, and immune modulation markers) to achieve higher sensitivity and accuracy than any single biomarker could provide alone.
Solution Approach 2:
The patent creates a composite predictive model that functions like a composite material - combining multiple biomarker components with different properties to achieve enhanced overall performance. The multivariate panel acts as a composite system where each biomarker contributes specific information about different aspects of disease activity, resulting in a more robust and sensitive prediction tool.
2Measurement precision
If individual biomarkers are used, then the test is easy to perform, but the specificity for differentiating MS from other neurological conditions is poor
Solution Approach 1:
The patent merges multiple biomarkers with different specificities into a single predictive panel. By combining biomarkers that respond to different aspects of multiple sclerosis pathology (neurodegeneration, inflammation, immune modulation), the panel achieves high specificity for differentiating MS from other neurological conditions, as the collective pattern of biomarker expression is unique to MS disease activity.
Solution Approach 2:
The patent applies local quality by selecting biomarkers that specifically target different pathological processes in MS. Each biomarker in the panel has a specific function - some detect neurodegeneration, others detect inflammation, and others detect immune modulation - and this specialized distribution of functions across the panel enhances overall specificity for MS diagnosis and monitoring.
3Reliability
If a multivariate biomarker panel is used to improve predictive power, then the ability to detect subtle disease activity increases, but the complexity of the testing system increases
Solution Approach 1:
The patent merges multiple biomarkers into a single integrated predictive panel that delivers enhanced predictive power for multiple sclerosis disease activity. This consolidation approach maintains reliability by combining complementary biomarkers that together provide a more accurate and robust prediction than individual markers, while presenting a unified testing interface that manages complexity.
Data Source
AI summary
Disclosed herein are methods for analzying quantitative expression values of biomarkers of a biomarker panel for determining disease activity in a human subject. Further disclosed herein are kits for measuring quantitative expression values of the markers as well as computer systems and software embodiments of predictive models for determining disease activity in human subjects based on the quantitative expression values of the markers.